Author

K. A. Donovan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 1 Assay:cryo-EM· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:microscopy & imaging analysis· 1 Organism:mouse· 1

Frequent Co-Authors

E. S. Fischer· 5 shared N. S. Gray· 3 shared B. J. Groendyke· 2 shared B. L. Ebert· 2 shared H. Yoon· 2 shared R. Lumpkin· 2 shared R. P. Nowak· 2 shared A. Choudhary· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBiochemistry

E. S. Fischer

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders

Y.-D. Li, M. W. Ma, M. M. Hassan, M. Hunkeler, M. Teng, K. Puvar, R. Lumpkin, B. Sandoval, C. Y. Jin, S. B. Ficarro, M. Y. Wang, S. Xu, B. J. Groendyke, L. H. Sigua, I. Tavares, , B. L. Ebert

This paper describes a new mechanism for molecular glue degraders called template-assisted covalent modification, showing how BRD4 degraders recruit CUL4DCAF16 to degrade BRD4.

bioRxiv · Feb 14, 2023Biochemistry

Development and utility of a PAK1-selective degrader

H.-Y. Chow, S. Karchugina, B. J. Groendyke, S. Toenjes, J. Hatcher, K. A. Donovan, E. S. Fischer, G. Abalakov, B. Faezov, R. L. Dunbrack, N. S. Gray, J. Chernoff

This study develops a PAK1-selective degrader, BJG-05-039, which shows enhanced anti-proliferative effects compared to the parent inhibitor NVS-PAK1-1 in PAK1-dependent cell lines.

bioRxiv · May 12, 2022Cancer Biology

Proteolysis Targeting Chimeras With Reduced Off-targets

T. M. Nguyen, V. Sreekanth, A. Deb, P. Kokkonda, P. K. Tiwari, K. A. Donovan, V. M. Shoba, S. K. Chaudhary, J. A. M. Mercer, S. Lai, A. Sadagopan, M. Jan, E. S. Fischer, D. R. Liu, B. L. Ebert, A. Choudhary

This study develops a platform to identify off-target degradation of ZF proteins by PROTACs and identifies design rules to reduce off-target effects using pomalidomide analogs.

bioRxiv · Nov 18, 2021Pharmacology & Toxicology

Targeted degradation of the oncogenic phosphatase SHP2

V. Vemulapalli, K. A. Donovan, T. Seegar, J. M. Rogers, M. Bae, R. Lumpkin, R. Cao, M. Henke, E. S. Fischer, G. Cuny, S. C. Blacklow

This paper develops a SHP2 PROTAC that degrades SHP2 in leukemic cells, inhibits MAPK signaling, and suppresses cancer growth.

bioRxiv · Jun 2, 2021 · PreprintBiochemistry

Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15

T. Faust, H. Yoon, R. P. Nowak, K. A. Donovan, Z. Li, Q. Cai, N. A. Eleuteri, T. Zhang, N. S. Gray, E. S. Fischer

The paper reveals how E7820 promotes RBM39 degradation via DCAF15 by binding to a non-conserved pocket on DCAF15, bypassing the need for high-affinity ligands.

bioRxiv · Aug 16, 2019Biochemistry